One of Deepbridge Capitals Technology Growth EIS companies, AlgaeCytes Limited, was featured in Mitteldeutsche Zeitung (a regional daily newspaper for southern Saxony-Anhalt, Germany) highlighting AlgaeCytes project to build its first commercial production plant in Dessau, Germany. Construction is expected to commence in 2022 and operations in late 2022 / early 2023.
Andrew J. Cosentino, Managing Director of AlgaeCytes Germany GmbH, commented: "The plant site choice was driven by the cooperation and support of the governments of the State of Sachsen-Anhalt, Germany and the City of Dessau-Rosslau, Germany, the intellectual resources in Algae Biotechnology offered by the Anhalt University of Applied Sciences, the available site and the location of Dessau-Rosslau relative to EU markets.”
AlgaeCytes will use its patented, proprietary technology to grow natural, freshwater algae in the controlled and protected environment of an enclosed photobioreactor system. Sustainable, traceable, plant-based, non-GMO algae-derived products will include Omega-3 EPA oils and other premium products primarily for the nutraceutical, personal care and pharmaceutical markets.
Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).